ANTIPLATELET THERAPY WITH CLOPIDOGREL TAKING INTO ACCOUNT CYP2C19 GENETIC POLYMORPHISMS IN PATIENTS WITH CORONARY HEART DISEASE AFTER CORONARY ARTERY STENTING

被引：1
|
作者：
Uzokov, J. [1 ]
Alyavi, B. [2 ]
Abdullaev, A. [1 ]
Muxitdinova, O. [2 ]
Ubaydullaeva, Z. [1 ]
机构：
[1] Republican Specialized Sci Pact Med Ctr Therapy &, Cardiol, Tashkent, Uzbekistan
[2] Tashkent Pediat Med Inst, Cardiol, Tashkent, Uzbekistan
来源：
ATHEROSCLEROSIS | 2021年 / 331卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P652
引用
收藏
页码：E265 / E265
页数：1
相关论文
共 50 条
  • [1] Clopidogrel efficacy after percutaneous coronary interventions considering with cyp2c19 genetic polymorphisms in patients with coronary heart disease
    Uzokov, J.
    Alyavi, B.
    Abdullaev, A.
    Rasulov, Y.
    Ortikov, J.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2022, 52
  • [2] CLOPIDOGREL EFFICACY AFTER PERCUTANEOUS CORONARY INTERVENTIONS CONSIDERING WITH CYP2C19 GENETIC POLYMORPHISMS IN PATIENTS WITH CORONARY HEART DISEASE
    Uzokov, J.
    Alyavi, B.
    Abdullaev, A.
    Orziev, D.
    Madjitov, I.
    ATHEROSCLEROSIS, 2022, 355 : E276 - E276
  • [3] CYP2C19 GENETIC POLYMORPHISM ON CLOPIDOGREL RESPONSE IN VIETNAMESE PATIENTS WITH CORONARY STENTING
    Kim, N. T.
    Nguyen, M. N. T.
    Do, D. L.
    Nguyen, Q. H.
    Nguyen, T. T. T.
    Truong, T. H.
    ATHEROSCLEROSIS, 2020, 315 : E83 - E84
  • [4] CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt
    Shawky, Ahmed
    Sabit, Hussein
    Nazih, Mahmoud
    Baraka, Khalid
    El-Zawahry, Mokhtar
    JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH, 2023, 13 (02) : 374 - 383
  • [5] CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt
    Ahmed Shawky
    Hussein Sabit
    Mahmoud Nazih
    Khalid Baraka
    Mokhtar El-Zawahry
    Journal of Epidemiology and Global Health, 2023, 13 (2) : 374 - 383
  • [6] Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease
    Cheng, Yujing
    Sun, Yan
    Zhang, Dai
    Ma, Xiaoteng
    Liu, Chi
    Hu, Chengping
    Sun, Tienan
    Zhao, Ziwei
    Liu, Xiaoli
    Zhou, Yujie
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [7] Influence of CYP2C19 genotype on antiplatelet treatment outcomes after percutaneous coronary intervention in patients with coronary heart disease
    Yu, Dongbiao
    Ma, Likun
    Zhou, Junling
    Li, Longwei
    Yan, Wu
    Yu, Xiaofan
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 19 (05) : 3411 - 3418
  • [8] Association between CYP2C19 gene polymorphisms and clopidogrel resistance in Chinese elderly patients with coronary heart disease
    Wu, F.
    Cao, J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015, 63 : S31 - S31
  • [9] CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention
    Liu, Tao
    Yin, Tao
    Li, Yan
    Song, Li-Qiang
    Yu, Jin
    Si, Rui
    Zhang, Ying-Mei
    He, Yuan
    Guo, Wen-Yi
    Wang, Hai-Chang
    CORONARY ARTERY DISEASE, 2014, 25 (05) : 412 - 420
  • [10] The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism
    Bockeria, O. L.
    Kudzoeva, Z. F.
    Shvarts, V. A.
    Koasari, A. K.
    Donakanyan, S. A.
    TERAPEVTICHESKII ARKHIV, 2016, 88 (05) : 47 - 54
12345